National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 35 of 66
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00778167
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
NCT00735917
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00608361
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00738881
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
NCT00775268
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00601900
Pharmacokinetic Studies Participation Survey
NCT00923468
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
NCT00748657
Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
NCT00924313
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00742625
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
NCT00602043
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
NCT00729586
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00723255
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT00729157
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
NCT00471536
Study of 9cUAB30 in Healthy Participants
NCT00896974
Resveratrol in Healthy Adult Participants
NCT00721877
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00735930
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
NCT00923949
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
NCT00684983
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00720109
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
NCT00703664
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
NCT00727233
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
NCT00666562
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
NCT00754494
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
NCT00650923
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
NCT00641706
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
NCT00971789
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00719901
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT00906360
Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer
NCT00923741
T-Cell Project: Epidemiologic Component
NCT00705809
Montelukast to Treat Bronchiolitis Obliterans
NCT00656058
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
NCT00693992
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
NCT00720174
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
NCT00703300
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
NCT00679354
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
NCT00718809
Sunitinib to Treat Recurrent Brain Cancer
NCT00923117
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
NCT00706992
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00684996
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
NCT00670748
Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-hour Recall
NCT01164254
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
NCT01445418
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00475150
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
NCT00678769
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
NCT00678132
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00698815
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
NCT00602277
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
NCT00666588
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.